Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses and seven patients with prolonged stable disease Efficacy and tolerability data from dose escalation and... | May 25, 2023

Related Keywords

Chicago ,Illinois ,United States ,Montreal ,Quebec ,Canada ,Texas ,American ,Julie Schneiderman ,Christian Marsolais ,Philippe Dubuc ,Communications Corporate Affairs ,Theratechnologies Inc ,University Of Texas Md Anderson Cancer Center ,American Society Of Clinical Oncology ,Drug Administration ,Department Of Investigational Cancer Therapeutics ,American Society ,Clinical Oncology ,Senior Vice President ,Chief Medical Officer ,Funda Meric Bernstam ,Investigational Cancer Therapeutics ,Saturday June ,Developmental Therapeutics ,Targeted Agents ,Tumor Biology ,Sudocetaxel Zendusortide ,Fast Track ,Forward Looking Statements ,Looking Statements ,Annual Information Form ,Vice President ,Chief Financial ,Theratechnologies Inc Stock Exchange ,News ,Information ,Press Release ,Reliminary ,Signs ,F ,Antitumor ,Activity ,Oted ,N ,Ith ,Two ,Artial ,Responses ,End ,Seven ,Patients ,Bprolonged ,Table ,Disease ,Efficacy ,Tolerability ,Data ,Rom ,Nose ,Scalation Th Ca88338h1001 ,